Cancer-related inflammation and treatment effectiveness

The Lancet Oncology

Volumn 15, Issue 11, 2014, Pages e493-e503

  Diakos, Connie I ^a   Charles, Kellie A ^b   McMillan, Donald C ^c   Clarke, Stephen J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; BMS 936559; BORTEZOMIB; CANCER VACCINE; CEDIRANIB; DEXAMETHASONE; DOVITINIB; ETANERCEPT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 6; IPILIMUMAB; LENVATINIB; NINTEDANIB; NONSTEROID ANTIINFLAMMATORY AGENT; PACRITINIB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; RUXOLITINIB; SILTUXIMAB; SIPULEUCEL T; SORAFENIB; SUNITINIB; TASQUINIMOD; TRABECTEDIN; UNINDEXED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; BONE MARROW CELL; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CELL INFILTRATION; CELL MEDIATED CYTOTOXICITY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MEGADOSE; EPITHELIAL MESENCHYMAL TRANSITION; FEVER; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; KIDNEY CARCINOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MALNUTRITION; MELANOMA; MESOTHELIOMA; METASTATIC MELANOMA; MYELOFIBROSIS; MYELOMA; NATURAL KILLER CELL; NIGHT SWEAT; OVARY CANCER; PARANEOPLASTIC SYNDROME; PROGNOSIS; PROSTATE CANCER; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR MICROENVIRONMENT; TUMOR NECROSIS; WEIGHT REDUCTION; COMPUTER ASSISTED RADIOTHERAPY; DISEASE COURSE; FEMALE; IMMUNOLOGY; INNATE IMMUNITY; MALE; NEOPLASMS; PATHOLOGY; PROCEDURES; PROSTATECTOMY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; WATCHFUL WAITING;

ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS; PROSTATECTOMY; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84908149118     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70263-3     Document Type: Review

References (92)

1. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Roxburgh CS, McMillan DC The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012, 38:451-466.
3. Mei Z, Liu Y, Cui A, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systemic review and meta-analysis. Br J Cancer 2014, 110:1595-1605.
4. McMillan DC The systemic inflammation-based Glasgow prognosis score: a decade of experience in patients with cancer. Cancer Treat Rev 2013, 39:534-540.
5. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013, 88:218-230.
6. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
7. Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC The prognostic value of histological tumour necrosis in solid organ malignant disease: a systematic review. Future Oncol 2011, 7:1223-1235.
8. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumour stage, size, grade and necrosis: the SSIGN score. J Urol 2002, 168:2395-2400.
9. Fisher ER, Palekar AS, Gregorio RM, Redmond C, Fisher B Pathological findings from the national surgical adjuvant breast project (protocol no. 4). IV. Signficance of tumour necrosis. Hum Pathol 1978, 9:523-530.
10. Richards CH, Roxburgh CS, Anderson JH, et al. Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. Br J Surg 2012, 99:287-294.
11. Kolb R, Liu GH, Janoswki AM, Sutterwala FS, Zhang W Inflammasomes in cancer: a double-edged sword. Protein Cell 2014, 5:12-20.
12. Henao-Mejia J, Elinav E, Strowig T, Flavell RA Inflammasomes: far beyond inflammation. Nature Immunol 2012, 13:321-324.
13. Terlizzi M, Casolaro V, Pinto A, Sorrentino R Inflammasome: cancer's friend or foe?. Pharmacol Ther 2014, 143:24-33.
14. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1b induces gastric inflammation and cancer and mobilises myeloid-derived suppressor cells in mice. Cancer Cell 2008, 14:408-419.
15. Terme M, Ulrich E, Aymeric L, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011, 71:5393-5399.
16. Palma G, Barbieri A, Bimonte S, et al. Interleukin 18: friend or foe in cancer. Biochim Biophys Acta 2013, 1836:296-303.
17. Germano G, Allavena P, Mantovani A Cytokines as a key component of cancer-related inflammation. Cytokine 2008, 43:374-379.
18. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12:253-268.
19. Larrivée B, Pollet I, Karsan A Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor. J Immunol 2005, 175:3015-3024.
20. Morishima T, Watanabe K, Niwa A, et al. Neutrophil differentiation from human-induced pluripotent stem cells. J Cell Physiol 2011, 226:1283-1291.
21. Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer?. Cancer Treat Rev 2013, 39:89-96.
22. Richards CH, Flegg K, Roxburgh CS, et al. The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer 2012, 106:2010-2015.
23. Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 2012, 107:864-873.
24. Putoczki T, Thiem S, Loving A, et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 2013, 24:257-271.
25. Taniguchi K, Karin M IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014, 26:54-74.
26. DiDonato JA, Mercurio F, Karin M NF-kB and the link between inflammation and cancer. Immunol Rev 2012, 246:379-400.
27. Grivennikov SI, Karin M Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2009, 20:65-71.
28. Klintrup K, Makinen J, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005, 41:2645-2654.
29. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density and location of immune cells within human colorectal tumours predict clinical outcome. Science 2006, 313:1960-1964.
30. Michael-Robinson JM, Biemer-Huttmann A, Purdie DM, et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001, 48:360-366.
31. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol 2014, 25:644-651.
32. Mandruzzato S, Solito S, Falisi E, et al. IL4Ra+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009, 182:6562-6568.
33. Laird BJ, McMillan DC, Fayers P, et al. The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist 2013, 18:1050-1055.
34. Iida N, Dzutsev A, Stewart CA, et al. Commensal bacterial control cancer response to therapy by modulating the tumour microenvironment. Science 2013, 342:967-970.
35. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013, 342:971-976.
36. Heikkila K, Ebrahim S, Lawlor DA A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007, 61:824-833.
37. Tsilidis KK, Branchini C, Guallar E, Hetzlouer KJ, Erlinger TP, Platz EA C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008, 123:1133-1140.
38. Beer TM, Lalani AS, Lee S, et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer. Cancer 2008, 112:2377-2383.
39. Saito K, Kihara K C-reactive proteins as a biomarker for urological cancers. Nat Rev Urol 2011, 8:659-666.
40. Roxburgh CSD, McDonald A, Salmond J, et al. Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. Int J Colorectal Dis 2011, 26:483-492.
41. Michael M, Goldstein D, Clarke SJ, et al. Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. Clin Colorectal Cancer 2006, 6:297-304.
42. Chua W, Charles KA, Baracos VE, Clarke SJ Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011, 104:1288-1295.
43. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010, 16:5805-5813.
44. Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 2007, 97:1266-1270.
45. Shi C, Pamer EG Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011, 11:762-774.
46. Peranzoni E, Zilio S, Marigo I, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010, 22:238-244.
47. Ohki S, Shibata M, Gonda K, et al. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol Rep 2012, 28:453-458.
48. Diaz-Montero CM, Labib Salem M, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumour burden, and doxocubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58:49-59.
49. Tel J, Anguille S, Waterborg CE, Smits EL, Figdor CG, de Vries JM Tumoricidal activity of human dendritic cells. Trends Immunol 2014, 35:38-46.
50. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome study. Eur J Cancer 2011, 47:2633-2641.
51. MacDonald N Terminology in cancer cachexia: importance and status. Curr Opin Nutr Metab 2012, 15:220-225.
52. Slaviero KA, Clarke SJ, Rivory LP Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003, 4:224-232.
53. Alexandre J, Gross-Goupil M, Falissard B, et al. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 2003, 14:36-41.
54. Roxburgh CS, McMillan DC Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer 2014, 110:1409-1412.
55. Chan AT, Detering E An emerging role for anti-inflammatory agents for chemoprevention. Prospects for chemoprevention of colorectal neoplasia 2013, 1-5. Springer-Verlag, Heidelberg. A.T. Chan, E. Detering (Eds.).
56. Solheim TS, Fearon KC, Blum D, Kaasa S Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol 2013, 52:6-17.
57. Forget P, Machiels JP, Coulie PG, et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung and kidney cancer surgery. Ann Surg Oncol 2013, 20(suppl 3):S650-S660.
58. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379:1591-1601.
59. Chia WK, Ali R, Toh HC Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol 2012, 9:561-570.
60. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumour PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012, 367:1596-1606.
61. Seufert BL, Poole EM, Whitton J, et al. IkBKb and NFkB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. Carcinogenesis 2013, 34:79-85.
62. Lonnroth C, Andersson M, Arvidsson A, et al. Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumour tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 2008, 8:5-15.
63. Leggas M, Kuo KL, Robert F, et al. Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy. Cancer Chemother Pharmacol 2009, 63:731-743.
64. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007, 25:3462-3468.
65. Samadder NJ, Mukherjee B, Huang SC, et al. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk of statin and NSAID use. Cancer 2011, 117:1640-1648.
66. Jain MK, Ridker PM Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005, 4:977-987.
67. Kwak B, Mulhaupt F, Myit S, Mach F Statins as a newly recognised type of immunomodulator. Nat Med 2000, 6:1399-1402.
68. Mbeunki F, Johann DJ Cancer and the tumour microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 2009, 63:571-582.
69. Trikha M, Corringham R, Klein B, Rossi JF Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003, 9:4653-4665.
70. Cowards J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011, 17:6083-6096.
71. Ando K, Takahashi F, Motojima S, et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol 2013, 31:e69-e72.
72. Brown ER, Charles KA, Hoare SA, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-a inhibitor, in patients with advanced cancer. Ann Oncol 2008, 19:1340-1346.
73. Germano G, Mantovani A, Allavena P Targeting of the innate immunity/inflammation as complementary anti-tumour therapies. Ann Med 2011, 43:581-593.
74. Onuffer JJ, Horuk R Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol Sci 2002, 23:459-467.
75. Ryan CW, Desai J The past, present and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma. Am Soc Clin Oncol Educ Book 2013, 386-393.
76. Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumour activity of trabectedin. Cancer Cell 2013, 23:249-262.
77. Dieci MV, Arnedos M, Andre F, Soria JC Fibroblast growth factor receptor inhibitors as a cancer treatment: from biological rationale to medical perspectives. Cancer Discov 2013, 3:264-279.
78. Konstantinopoulos PA, Papavassilious AG Seeing the future of cancer-associated transcription factor drug targets. JAMA 2011, 305:2349-2350.
79. Fagard R, Metelev V, Souissi I, Baran-Marszak F STAT3 inhibitors for cancer therapy. Have all roads been explored?. JAKSTAT 2013, 2:e22882.
80. Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomised, double-blind, placebo-controlled trial. J Clin Oncol 2013, 31:1285-1292.
81. Quintarelli C, De Angelis B, Errichiello S, et al. Selective strong synergism of ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. Leuk Res 2014, 38:1285-1292.
82. Tam CS, Verstovsek S Investigational janus kinase inhibitors. Expert Opin Investig Drugs 2013, 22:687-699.
83. Bosman MC, Schuringa JJ, Quax WJ, Vellenga E Bortezomib sensitivity of acute myeloid leukemia CD34+ cells can be enhanced by targeting the persisting activity of NF-kB and the accumulation of MCL-1. Exp Hematol 2013, 41:530-538.
84. Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY Therapeutic cancer vaccines: past, present, and future. Advances in cancer research 2013, 421-475. Elsevier, Amsterdam. K.D. Tew, P.B. Fisher (Eds.).
85. Pachucki J, Banchereau J Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013, 39:38-48.
86. Small EJ, Schelhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24:3089-3094.
87. Aarntzen EH, De Vries IJ, Lesterhuis WJ, et al. Targeting CD4+ T-helper cells improves the induction of antitumour responses in dendritic cell-based vaccination. Cancer Res 2012, 73:19-29.
88. Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol 2012, 2012:492920.
89. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilumumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
90. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011, 77:12-19.
91. Pili R, Haggman M, Stadler WM, et al. Phase II randomised, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2012, 29:4022-4028.
92. Limaverde-Sousa G, Sternberg C, Ferreira CG Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev 2014, 40:548-557.